HaemoDYNAMICs in Primary and Secondary Hypertension
-
- STATUS
- Recruiting
-
- End date
- Dec 31, 2025
-
- participants needed
- 2000
-
- sponsor
- Tampere University
Summary
The primary aim of the present study was to examine the haemodynamic changes in primary hypertension and secondary hypertension (renal diseases, endocrine diseases, obesity-associated hypertension) with a non-invasive haemodynamic measurement protocol utilizing radial pulse wave analysis and whole-body impedance cardiography in both supine position and during head-up tilt. For comparison, haemodynamics of subjects with chronic fatigue syndrome will also be recorded.
Description
Elevated blood pressure (BP) and related cardiovascular complications are the leading causes of morbidity and mortality in the modern world. In routine clinical practice, the haemodynamic status is commonly assessed by measuring heart rate and blood pressure at rest, which provides only limited information about functional haemodynamic status. In addition, the haemodynamic changes resulting in similar elevations of BP may differ substantially between patients and disorders.
Therefore, we investigated the haemodynamic changes in primary and secondary hypertension and in the control subjects with non-invasive radial pulse wave analysis and whole-body impedance cardiography. The method includes the determination of volume status using bioimpedance spectroscopy, determination of peripheral and central BP, cardiac function, vascular resistance, arterial compliance and indices of pulse wave reflection. Besides the measurements performed in the supine position, passive orthostatic challenge is included in the protocol to assess the upright functional haemodynamic status.
The repeatability and reproducibility of the protocol was first examined with a double-blind, randomized protocol in 35 subjects (methodological study group), and after that the administration of research drugs has been open-label. The effects of single doses of two largely endothelium-dependent agents, inhaled salbutamol and intravenous L-arginine, and one endothelium-independent agent, sublingual nitroglycerin, were investigated. However, challenges with the acute dosing of all medical compounds was terminated at the end of December 2016. Thereafter, the measurement protocol has included supine and upright recordings on the tilt-table, followed by supine measurements during paced breathing (15 breaths per minute for 5 minutes, 6 breaths per minute for 5 minutes) that modulate the autonomic nervous tone.
The study population has consisted of subgroups described below. The study protocol of each subgroup has been approved by the ethics committee of the Pirkanmaa Hospital District (Ethics committee ID's above), and the administration of research drugs has also been approved by the Finnish Agency for Medicines (EudraCT-numbers above).
Details
| Condition | kidney insufficiency, Kidney Failure (Pediatric), Renal Dysfunction, aortic valve stenosis, Aortic Stenosis, Primary Hypertension, renal insufficiency, Kidney Disease, Impaired Renal Function, Nephropathy, Kidney Failure, Kidney Disease (Pediatric), Essential Hypertension, Renal Failure, VALVULAR HEART DISEASE, Renal Impairment, Secondary Hypertension, Heart Valve Disease |
|---|---|
| Treatment | Nitroglycerin 0.25 mg (single dose), Salbutamol 400 µg (single dose), L-arginine (10 min infusion), Liquorice (2 weeks, glycyrrhizin 290-370 mg daily), Small milk casein-derived polypeptides (12 weeks daily), Bisoprolol (5mg daily for 3 weeks), Nitroglycerin 0.25 mg (single dose, no longer given since January 2017), Salbutamol 400 µg (single dose, no longer given since January 2017), L-arginine (10 min infusion, no longer given since January 2017), Liquorice (2 weeks, glycyrrhizin 290-370 mg daily, no longer given since 2012), Small milk casein-derived polypeptides (12 weeks daily, recordings completed 2011), Bisoprolol (5 mg daily for 3 weeks, recordings completed 2011) |
| Clinical Study Identifier | NCT01742702 |
| Sponsor | Tampere University |
| Last Modified on | 28 August 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer